Washington Manual of Medical Therapeutics
Anti-COVID-19 Agents
To view the entire topic, please log in or purchase a subscription.
The Washington Manual is an award-winning, complete mobile solution for nurses and students. Look up information on diseases, tests, and procedures; then consult the database with 5,000+ drugs or refer to 65,000+ dictionary terms. Explore these free sample topics:
-- The first section of this topic is shown below --
Treatment
Remdesivir (200 mg IV × 1, then 100 mg IV q24h × 5–10 days) is a SARS-CoV-2 nucleotide analog RNA polymerase inhibitor that is FDA-approved for treatment of COVID-19 disease necessitating hospitalization. Remdesivir should not be routinely administered to patients with an estimated GFR <30 mL/min due to risk of the drug’s delivery vehicle accumulating. The main adverse events of importance include the potential for hypersensitivity reactions during and after drug administration and hepatic transaminase elevations.
-- To view the remaining sections of this topic, please log in or purchase a subscription --
Treatment
Remdesivir (200 mg IV × 1, then 100 mg IV q24h × 5–10 days) is a SARS-CoV-2 nucleotide analog RNA polymerase inhibitor that is FDA-approved for treatment of COVID-19 disease necessitating hospitalization. Remdesivir should not be routinely administered to patients with an estimated GFR <30 mL/min due to risk of the drug’s delivery vehicle accumulating. The main adverse events of importance include the potential for hypersensitivity reactions during and after drug administration and hepatic transaminase elevations.
There's more to see -- the rest of this topic is available only to subscribers.
